<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The leucocyte antigen CD23 is upregulated in the early stages of B-cell activation by Interleukin-4 (IL-4), and functions as an IgE receptor and lymphocyte growth factor </plain></SENT>
<SENT sid="1" pm="."><plain>We have studied the expression of CD23 in 68 cases of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) using the antibody BU38 </plain></SENT>
<SENT sid="2" pm="."><plain>This new antibody has the great advantage of being applicable to routinely-processed paraffin sections </plain></SENT>
<SENT sid="3" pm="."><plain>CD23 was expressed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells in 27 out of 36 cases of low grade NHL and 3 out of 32 cases of high grade NHL </plain></SENT>
<SENT sid="4" pm="."><plain>Follicular dendritic cells were strongly positive and were seen in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Macrophages were also positive and were numerous in high grade lesions </plain></SENT>
</text></document>